<code id='8B47378EAD'></code><style id='8B47378EAD'></style>
    • <acronym id='8B47378EAD'></acronym>
      <center id='8B47378EAD'><center id='8B47378EAD'><tfoot id='8B47378EAD'></tfoot></center><abbr id='8B47378EAD'><dir id='8B47378EAD'><tfoot id='8B47378EAD'></tfoot><noframes id='8B47378EAD'>

    • <optgroup id='8B47378EAD'><strike id='8B47378EAD'><sup id='8B47378EAD'></sup></strike><code id='8B47378EAD'></code></optgroup>
        1. <b id='8B47378EAD'><label id='8B47378EAD'><select id='8B47378EAD'><dt id='8B47378EAD'><span id='8B47378EAD'></span></dt></select></label></b><u id='8B47378EAD'></u>
          <i id='8B47378EAD'><strike id='8B47378EAD'><tt id='8B47378EAD'><pre id='8B47378EAD'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:13
          Illustration of business people chasing flying money with butterfly nets
          Adobe

          SAN FRANCISCO — Hospital leaders spent a good chunk of their stage time at the J.P. Morgan Healthcare Conference talking up their billions in cash and investment reserves.

          It’s a decidedly different message than the one they convey to their communities, or to Congress when they lobby for more funding. But at the high-profile health care industry conference here, nonprofit health systems need to sell investors on their message of strength and resilience. And since they certainly can’t do that by focusing on patient care — an area where they’re barely breaking even or losing money — cash and investments is the way to do it.

          advertisement

          “For those of you who hold our debt, taxable and tax-exempt, thank you,” John Mordach, the chief financial officer of Jefferson Health, said during his presentation on Tuesday. “For those who don’t, I think we’re a great, undervalued investment and we get a great return.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

          GwenPetersen,38,anALSpatient,believesthattherecentfailureofAmylyx'sdrugRelyvriocouldstillteachresear

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          The drug industry has found itself all alone in Washington

          MollyFergusonforSTATIfyou’readrugcompanyexecutive,youprobablyfeellikeyougotuponthewrongsideofbed.OnT